HOXB5 Overexpression Is Associated with Neuroendocrine Differentiation and Poor Prognosis in Prostate Cancer.
HOXB5
RB1
RET
neuroendocrine differentiation
p53
prostate cancer
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
26 Jul 2021
26 Jul 2021
Historique:
received:
30
06
2021
revised:
19
07
2021
accepted:
23
07
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
Homeobox genes function as master regulatory transcription factors during embryogenesis. HOXB5 is known to play an important role in several cancers. However, the biological role of HOXB5 in prostate cancer (PCa) is not fully elucidated. This study aimed to analyze the expression and function of HOXB5 and involvement of HOXB5 in neuroendocrine differentiation in PCa. Immunohistochemistry showed that 56 (43.8%) of 128 cases of localized PCa were positive for HOXB5. HOXB5-positive cases were associated with poor prostate-specific antigen recurrence-free survival after prostatectomy. Among 74 cases of metastatic PCa, 43 (58.1%) were positive for HOXB5. HOXB5 expression was higher in metastatic PCa than that in localized PCa. HOXB5 knockdown suppressed cell growth and invasion, but HOXB5 overexpression increased cell growth and invasion in PCa cell lines. Furthermore, HOXB5 regulated RET expression. Gene set enrichment analysis revealed that Nelson androgen response gene set was enriched in low HOXB5 expression group. RB1 knockout increased HOXB5 expression. Of note, additional p53 knockdown further increased HOXB5 expression in RB1 knockout cells. In silico analysis showed that HOXB5 expression was increased in neuroendocrine PCa (NEPC). These results suggest that HOXB5 may be a promising prognostic marker after prostatectomy and is involved in progression to NEPC.
Identifiants
pubmed: 34440097
pii: biomedicines9080893
doi: 10.3390/biomedicines9080893
pmc: PMC8389587
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Japan Society for the Promotion of Science
ID : 19K18586
Références
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Eur Urol. 2017 Apr;71(4):630-642
pubmed: 27591931
Eur Urol. 2013 Jul;64(1):173-6
pubmed: 23518396
CA Cancer J Clin. 2017 May 6;67(3):245-253
pubmed: 28222223
Development. 2013 Oct;140(19):3951-63
pubmed: 24046316
Int J Biochem Cell Biol. 2014 Jun;51:142-9
pubmed: 24794774
Dev Growth Differ. 2015 Feb;57(2):158-68
pubmed: 25703667
Mol Cancer. 2007 Jul 10;6:45
pubmed: 17623056
Clin Cancer Res. 2012 Feb 1;18(3):666-77
pubmed: 22156612
EBioMedicine. 2015 Jul 29;2(9):1133-44
pubmed: 26501111
JCO Precis Oncol. 2017 Jul;2017:
pubmed: 28825054
PLoS One. 2011;6(6):e20815
pubmed: 21677782
Eur J Surg Oncol. 2020 Jun;46(6):1066-1073
pubmed: 31864826
Cancers (Basel). 2021 Feb 09;13(4):
pubmed: 33572108
Cancer Res. 2014 Jun 15;74(12):3228-37
pubmed: 24713434
Cells. 2019 Jan 20;8(1):
pubmed: 30669516
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
Clin Cancer Res. 2017 Aug 15;23(16):4885-4896
pubmed: 28490466
J Clin Invest. 2013 Mar;123(3):1109-22
pubmed: 23426182
J Mol Med (Berl). 2014 Aug;92(8):811-23
pubmed: 24996520
Nat Med. 2016 Apr;22(4):369-78
pubmed: 26928463
Nucleic Acids Res. 2017 Jul 3;45(W1):W98-W102
pubmed: 28407145
Nat Genet. 2007 Jan;39(1):41-51
pubmed: 17173048
J Clin Oncol. 2018 Aug 20;36(24):2492-2503
pubmed: 29985747
Cancer Cell. 2010 Jul 13;18(1):11-22
pubmed: 20579941
Prostate. 2015 Dec;75(16):1868-76
pubmed: 26310814
J Nucl Med. 2008 Oct;49(10):1686-93
pubmed: 18794255
Eur Urol. 2015 Mar;67(3):470-9
pubmed: 25306226
J Clin Invest. 2019 Jul 30;129(10):4492-4505
pubmed: 31361600
Proc Natl Acad Sci U S A. 2019 Jun 4;116(23):11428-11436
pubmed: 31061129
Tumour Biol. 2020 May;42(5):1010428320918050
pubmed: 32456563
Mol Cancer Res. 2020 Aug;18(8):1176-1188
pubmed: 32461304
BMC Cancer. 2017 Nov 13;17(1):759
pubmed: 29132337
Oncology. 2019;97(3):164-172
pubmed: 31195398
Cell Rep. 2020 May 26;31(8):107669
pubmed: 32460015
Science. 2017 Jan 6;355(6320):84-88
pubmed: 28059768
Urology. 2003 Feb;61(2):365-9
pubmed: 12597949
Nature. 2012 Jul 12;487(7406):239-43
pubmed: 22722839
Nat Rev Urol. 2020 May;17(5):292-307
pubmed: 32203305
Oncol Res. 2018 Jan 19;26(1):37-44
pubmed: 28337958
Gastroenterology. 2008 Apr;134(4):1104-15
pubmed: 18395091
Am J Surg Pathol. 2016 Feb;40(2):244-52
pubmed: 26492179
Nat Med. 2016 Mar;22(3):298-305
pubmed: 26855148
Prostate Cancer Prostatic Dis. 2012 Jun;15(2):150-6
pubmed: 22343836
Cancer Cell. 2005 Nov;8(5):393-406
pubmed: 16286247
Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11890-5
pubmed: 12185249
Future Oncol. 2017 Jul;13(17):1505-1516
pubmed: 28766961
Prostate. 2019 Feb;79(2):234-242
pubmed: 30324761
Int J Mol Sci. 2021 Feb 20;22(4):
pubmed: 33672769
Nat Med. 2021 Mar;27(3):426-433
pubmed: 33664492
Cell. 2017 Jul 27;170(3):564-576.e16
pubmed: 28753430
Clin Cancer Res. 2015 Oct 15;21(20):4698-708
pubmed: 26071481
Anticancer Drugs. 2020 Sep;31(8):828-835
pubmed: 32796404
Int J Biol Sci. 2015 May 01;11(6):701-11
pubmed: 25999793